This study evaluates the safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bacteremia among subjects with renal impairment. While daptomycin is an FDA-approved drug that is commonly used, the study hopes to better understand the drug in patients who have either moderate (CLcr 30-50 mL/min) or severe (CLcr <30 mL/min) renal impairment.
Approximately 120 patients will be enrolled in the study at up to 30 sites in the United States. The Reading Hospital is currently enrolling patients in the study, which is expected to remain open until March 2012.
For more information, please call the Clinical Trials Office at 610-988-4308 or visit clinicaltrials.gov.